[{"orgOrder":0,"company":"Haukeland University Hospital","sponsor":"Niagen Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NORWAY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Licensing Agreement","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Neurology","graph2":"Phase III","graph3":"Haukeland University Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Haukeland University Hospital \/ Niagen Bioscience","highestDevelopmentStatusID":"10","companyTruncated":"Haukeland University Hospital \/ Niagen Bioscience"},{"orgOrder":0,"company":"Charite University, Berlin, Germany","sponsor":"Niagen Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Charite University, Berlin, Germany","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Charite University, Berlin, Germany \/ ChromaDex, Inc","highestDevelopmentStatusID":"1","companyTruncated":"Charite University, Berlin, Germany \/ ChromaDex, Inc"},{"orgOrder":0,"company":"Nutraceuticals Research Institute","sponsor":"Niagen Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nutraceuticals Research Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutraceuticals Research Institute \/ ChromaDex, Inc","highestDevelopmentStatusID":"1","companyTruncated":"Nutraceuticals Research Institute \/ ChromaDex, Inc"},{"orgOrder":0,"company":"KGK Science","sponsor":"Niagen Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Undisclosed","graph2":"Phase II","graph3":"KGK Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KGK Science \/ ChromaDex, Inc","highestDevelopmentStatusID":"8","companyTruncated":"KGK Science \/ ChromaDex, Inc"},{"orgOrder":0,"company":"KGK Science","sponsor":"Niagen Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Dietary Supplement","year":"2014","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Undisclosed","graph2":"Phase II","graph3":"KGK Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KGK Science \/ ChromaDex, Inc","highestDevelopmentStatusID":"8","companyTruncated":"KGK Science \/ ChromaDex, Inc"},{"orgOrder":0,"company":"Akershus University Hospital","sponsor":"The Bergesen Foundation | South-Eastern Norway Regional Health Authority | Sykehuset Innlandet HF | Oslo University Hospital | St. Olavs Hospital | Haukeland University Hospital | University Hospital of North Norway | University of Bergen","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NORWAY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Akershus University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akershus University Hospital \/ The Bergesen Foundation | South-Eastern Norway Regional Health Authority | Sykehuset Innlandet HF | Oslo University Hospital | St. Olavs Hospital | Haukeland University Hospital | University Hospital of North Norway | University of Bergen","highestDevelopmentStatusID":"8","companyTruncated":"Akershus University Hospital \/ The Bergesen Foundation | South-Eastern Norway Regional Health Authority | Sykehuset Innlandet HF | Oslo University Hospital | St. Olavs Hospital | Haukeland University Hospital | University Hospital of North Norway | University of Bergen"},{"orgOrder":0,"company":"Sinopharm","sponsor":"Niagen Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Sinopharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sinopharm \/ ChromaDex, Inc","highestDevelopmentStatusID":"15","companyTruncated":"Sinopharm \/ ChromaDex, Inc"},{"orgOrder":0,"company":"University of Copenhagen","sponsor":"Bispebjerg Hospital | Elysium Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University of Copenhagen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Copenhagen \/ Bispebjerg Hospital | Elysium Health","highestDevelopmentStatusID":"8","companyTruncated":"University of Copenhagen \/ Bispebjerg Hospital | Elysium Health"},{"orgOrder":0,"company":"University of Copenhagen","sponsor":"Bispebjerg Hospital | Elysium Health","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"University of Copenhagen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Copenhagen \/ Bispebjerg Hospital | Elysium Health","highestDevelopmentStatusID":"1","companyTruncated":"University of Copenhagen \/ Bispebjerg Hospital | Elysium Health"},{"orgOrder":0,"company":"University of Copenhagen","sponsor":"Elysium Health","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"University of Copenhagen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Copenhagen \/ Elysium Health","highestDevelopmentStatusID":"8","companyTruncated":"University of Copenhagen \/ Elysium Health"},{"orgOrder":0,"company":"Oslo University Hospital","sponsor":"Haukeland University Hospital | South-Eastern Norway Regional Health Authority | Klinbeforsk | The Dam Foundation | Elysium Health | NKS Olaviken Gerontopsychiatric Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NORWAY","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Oslo University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oslo University Hospital \/ Haukeland University Hospital | South-Eastern Norway Regional Health Authority | Klinbeforsk | The Dam Foundation | Elysium Health | NKS Olaviken Gerontopsychiatric Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Oslo University Hospital \/ Haukeland University Hospital | South-Eastern Norway Regional Health Authority | Klinbeforsk | The Dam Foundation | Elysium Health | NKS Olaviken Gerontopsychiatric Hospital"},{"orgOrder":0,"company":"Akershus University Hospital","sponsor":"ChromaDex, Inc | Norwegian Cancer Society | Norwegian Breast Cancer Association | Helse S\u00f8r-\u00d8st","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Oncology","graph2":"Phase II","graph3":"Akershus University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akershus University Hospital \/ ChromaDex, Inc | Norwegian Cancer Society | Norwegian Breast Cancer Association | Helse S\u00f8r-\u00d8st","highestDevelopmentStatusID":"8","companyTruncated":"Akershus University Hospital \/ ChromaDex, Inc | Norwegian Cancer Society | Norwegian Breast Cancer Association | Helse S\u00f8r-\u00d8st"},{"orgOrder":0,"company":"Haukeland University Hospital","sponsor":"Oslo University Hospital | Akershus Universitetssykehus HF | Vestre Viken Hospital Trust | Sykehuset Ostfold | Nevro Arendal AS | Helse Forde | Helse Fonna | Universitetssykehuset Nord Norge HF | Helse M\u00f8re og Romsdal HF | Nordlandssykehuset HF | Elysium ","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NORWAY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Neurology","graph2":"Phase II","graph3":"Haukeland University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haukeland University Hospital \/ Oslo University Hospital | Akershus Universitetssykehus HF | Vestre Viken Hospital Trust | Sykehuset Ostfold | Nevro Arendal AS | Helse Forde | Helse Fonna | Universitetssykehuset Nord Norge HF | Helse M\u00f8re og Romsdal HF | Nordlandssykehuset HF | Elysium ","highestDevelopmentStatusID":"8","companyTruncated":"Haukeland University Hospital \/ Oslo University Hospital | Akershus Universitetssykehus HF | Vestre Viken Hospital Trust | Sykehuset Ostfold | Nevro Arendal AS | Helse Forde | Helse Fonna | Universitetssykehuset Nord Norge HF | Helse M\u00f8re og Romsdal HF | Nordlandssykehuset HF | Elysium "},{"orgOrder":0,"company":"Oslo University Hospital","sponsor":"Niagen Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NORWAY","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Oslo University Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oslo University Hospital \/ ChromaDex, Inc","highestDevelopmentStatusID":"7","companyTruncated":"Oslo University Hospital \/ ChromaDex, Inc"},{"orgOrder":0,"company":"Haukeland University Hospital","sponsor":"Elysium Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NORWAY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Neurology","graph2":"Undisclosed","graph3":"Haukeland University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haukeland University Hospital \/ Elysium Health","highestDevelopmentStatusID":"1","companyTruncated":"Haukeland University Hospital \/ Elysium Health"},{"orgOrder":0,"company":"Haukeland University Hospital","sponsor":"Elysium Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NORWAY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Neurology","graph2":"Undisclosed","graph3":"Haukeland University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haukeland University Hospital \/ Elysium Health","highestDevelopmentStatusID":"1","companyTruncated":"Haukeland University Hospital \/ Elysium Health"},{"orgOrder":0,"company":"University of South Alabama","sponsor":"Elysium Health","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"University of South Alabama","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of South Alabama \/ Elysium Health","highestDevelopmentStatusID":"1","companyTruncated":"University of South Alabama \/ Elysium Health"},{"orgOrder":0,"company":"University of Oklahoma","sponsor":"University of Pennsylvania | Oklahoma Medical Research Foundation | Elysium Health","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"University of Oklahoma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Oklahoma \/ University of Pennsylvania | Oklahoma Medical Research Foundation | Elysium Health","highestDevelopmentStatusID":"11","companyTruncated":"University of Oklahoma \/ University of Pennsylvania | Oklahoma Medical Research Foundation | Elysium Health"},{"orgOrder":0,"company":"University of Texas Health Science Center at San Antonio","sponsor":"University of Texas System | South Texas Veterans Health Care System","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Neurology","graph2":"Undisclosed","graph3":"University of Texas Health Science Center at San Antonio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Texas Health Science Center at San Antonio \/ University of Texas System | South Texas Veterans Health Care System","highestDevelopmentStatusID":"1","companyTruncated":"University of Texas Health Science Center at San Antonio \/ University of Texas System | South Texas Veterans Health Care System"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Elysium Health","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Undisclosed","graph2":"Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Elysium Health","highestDevelopmentStatusID":"8","companyTruncated":"Mayo Clinic \/ Elysium Health"},{"orgOrder":0,"company":"Elysium Health","sponsor":"University of Pennsylvania","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Undisclosed","graph2":"Phase I","graph3":"Elysium Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elysium Health \/ University of Pennsylvania","highestDevelopmentStatusID":"6","companyTruncated":"Elysium Health \/ University of Pennsylvania"},{"orgOrder":0,"company":"Elysium Health","sponsor":"University of Exeter","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Undisclosed","graph2":"Phase I","graph3":"Elysium Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elysium Health \/ University of Exeter","highestDevelopmentStatusID":"6","companyTruncated":"Elysium Health \/ University of Exeter"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"University of Minnesota | Thorne HealthTech","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ University of Minnesota | Thorne HealthTech","highestDevelopmentStatusID":"1","companyTruncated":"Mayo Clinic \/ University of Minnesota | Thorne HealthTech"},{"orgOrder":0,"company":"Niagen Bioscience","sponsor":"Midwest Center for Metabolic and Cardiovascular Research","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Neurology","graph2":"Undisclosed","graph3":"Niagen Bioscience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Niagen Bioscience \/ Midwest Center for Metabolic and Cardiovascular Research","highestDevelopmentStatusID":"1","companyTruncated":"Niagen Bioscience \/ Midwest Center for Metabolic and Cardiovascular Research"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"HealthTech Connex Inc. | Thorne HealthTech","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Undisclosed","graph2":"Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ HealthTech Connex Inc. | Thorne HealthTech","highestDevelopmentStatusID":"8","companyTruncated":"Mayo Clinic \/ HealthTech Connex Inc. | Thorne HealthTech"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Sanford Health","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Undisclosed","graph2":"Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Sanford Health","highestDevelopmentStatusID":"8","companyTruncated":"Mayo Clinic \/ Sanford Health"},{"orgOrder":0,"company":"Donna Hammond","sponsor":"National Cancer Institute | ChromaDex, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Neurology","graph2":"Phase II","graph3":"Donna Hammond","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Donna Hammond \/ National Cancer Institute | ChromaDex, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Donna Hammond \/ National Cancer Institute | ChromaDex, Inc"}]
Find Clinical Drug Pipeline Developments & Deals for Nicotinamide Riboside
Details :
Niagen has secured an exclusive global license from Haukeland University to develop and commercialize Niagen (nicotinamide riboside) as a potential therapy for Parkinson’s disease.
Details :
Niagen is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Sponsor :
Haukeland University Hospital | South-Eastern Norway Regional Health Authority | Klinbeforsk | The Dam Foundation | Elysium Health | NKS Olaviken Gerontopsychiatric Hospital
Details :
Nicotinamide Riboside is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Huntington Disease.
Sponsor :
Haukeland University Hospital | South-Eastern Norway Regional Health Authority | Klinbeforsk | The Dam Foundation | Elysium Health | NKS Olaviken Gerontopsychiatric Hospital
Details :
Nicotinamide Riboside is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Supranuclear Palsy, Progressive.
Details :
Nicotinamide Riboside is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Details :
Niagen is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Details :
Nicotinamide Riboside is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.
Details :
Nicotinamide Riboside is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Aging.
Details :
Nicotinamide Riboside is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Aging.
Details :
Tru Niagen®, featuring Niagen®, is one of the top-selling brands in the Vitamin B3 category on Amazon U.S. for boosting NAD+ levels. Supplementation with Niagen® is backed by 20 published and peer-reviewed clinical trials.
Reset All
